Aerovate Therapeutics, Inc.
AVTE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $3,713 | $2,667 | $2,546 | $2,654 |
| - Cash | $50 | $221 | $44 | $34 |
| + Debt | $1 | $1 | $0 | $0 |
| Enterprise Value | $3,664 | $2,447 | $2,502 | $2,620 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | 50% |
| EBITDA | -$25 | -$28 | -$3 | -$6 |
| % Margin | – | – | – | -5,709.8% |
| Net Income | -$25 | -$32 | -$3 | -$5 |
| % Margin | – | – | – | -4,848.2% |
| EPS Diluted | -482.25 | -863.46 | -0.09 | -0.19 |
| % Growth | 44.1% | -959,300% | 52.6% | – |
| Operating Cash Flow | -$22 | -$37 | -$2 | -$11 |
| Capital Expenditures | -$0 | -$0 | $0 | $0 |
| Free Cash Flow | -$22 | -$37 | -$2 | -$11 |